Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Practice Guidelines

Background:

• Chronic Obstructive Pulmonary Disease (COPD) management evolves with new therapeutic options.
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides updated guidelines for COPD care.
• Novel pharmacotherapies are emerging for patients with persistent COPD symptoms.

Purpose of the Study:

• To summarize recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates.
• To review data on novel therapies and interventions for COPD.
• To highlight changes in optimal COPD management strategies.

Main Methods:

• Literature search of MEDLINE, Cochrane Reviews, and PubMed.
• Inclusion of English-language primary literature and review articles.
• Evaluation of Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines from 2001-2025 and novel agent package inserts.

Main Results:

• LAMA/LABA combination therapy is favored over monotherapy for initial COPD treatment.
• Inhaled corticosteroid (ICS) efficacy is enhanced in patients with blood eosinophils >300 cells/µL.
• Novel agents ensifentrine, dupilumab, and icenticaftor show promise in clinical trials for persistent COPD symptoms.
• The CAPTURE tool demonstrates efficacy in screening for unrecognized COPD.

Conclusions:

• Optimal COPD management includes LAMA/LABA therapy with judicious ICS use.
• Updated vaccine recommendations (RSV, pneumococcal) are crucial for COPD patients.
• Ensifentrine and dupilumab represent potential new treatment options.
• Pharmacists play a role in medication optimization, considering patient-specific factors and endotypes.
• Early identification tools like CAPTURE are important for patient assessment.